Evidence map›Paper›PMID 35175185›Full record

ArticleBlood transfusion = Trasfusione del sangue2022

SARS-CoV-2 and post-donation information: a one-year experience of the French haemovigilance network.

Pierre Cappy, Saadia Legrain-Jbilou, Lila Chabli, Melissa N'Debi, Pierre Gallian, Nadège Brisbarre, Josiane Pillonel, Pascal Morel, Syria Laperche

Open access · greenAbstract read
In one paragraph

Article in Blood transfusion = Trasfusione del sangue, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Insights and innovations in Blood Transfusion.Blood transfusion = Trasfusione del sangue · 2024
    Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Pierre CappyCentre National de Référence Risques Infectieux Transfusionnels, Institut National de la Transfusion Sanguine, Paris, France.
Saadia Legrain-JbilouEtablissement Français du Sang, La Plaine Saint-Denis, France.
Lila ChabliEtablissement Français du Sang, La Plaine Saint-Denis, France.
Melissa N'DebiLaboratoire de Virologie, Hôpitaux Universitaire Henri Mondor, Paris, France.
Pierre GallianEtablissement Français du Sang, La Plaine Saint-Denis, France.
Nadège BrisbarreUnité des Virus Émergents (UVE) Aix-Marseille Université - IRD 190 - Inserm 1207 - IHU Méditerranée Infection, Marseille, France.
Josiane PillonelSanté Publique France, Département des maladies infectieuses, Saint-Maurice, France.
Pascal MorelEtablissement Français du Sang, La Plaine Saint-Denis, France.
Syria LapercheCentre National de Référence Risques Infectieux Transfusionnels, Institut National de la Transfusion Sanguine, Paris, France.
Établissement Français du Sang · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is growing evidence to support the hypothesis that SARS-CoV-2 is probably not transmissible by blood transfusion. In this study, we use the data gathered over one year by the French haemovigilance network on post-donation information related to SARS-CoV-2, and virological investigations on corresponding plasma to explore viral transmission by transfusion. MATERIALS AND

methodsWhenever a donor reported COVID-19 symptoms and/or a positive SARS-CoV-2 nasopharyngeal (NP) PCR test, information regarding diagnosis and symptoms was collected using a specific questionnaire, and repository plasmas were screened using the SARS-COV-2 R-GENE

resultsWe investigated 1,092 SARS-CoV-2-related post-donation information (PDI) reports. PDI donors were younger than the global donor population and donated more often in the Paris region. Sixty-eight percent reported a positive NP real-time (RT)-PCR or antigenic testing and 22% of these also had symptoms at the time of testing. Thirty-seven (3.4%) donations tested positive for SARS-CoV-2 RNA, 11 (30%) were confirmed by another molecular assay, and 7 (19%) by sequencing, confirming low viral level. Most RNAemic blood donors donated in southern regions and in Paris. There was no difference in demographic data or duration parameter between RNAemic and non-RNAemic donors. Duration parameter was determined as the time elapsed between donation and: i) the onset of symptoms; ii) a positive NP RT-PCR; and iii) PDI. Cell culture experiments did not show any infectivity related to RNAemic plasmas. DISCUSSION: SARS-CoV-2 RNA can be detected in a small fraction of blood donors with PDI, reporting very low levels of RNA. The corresponding plasma is probably not infectious. These findings highlight the value of haemovigilance and PDI to guide blood safety strategies.

Indexed as

COVID-19SARS-CoV-2Blood DonorsBlood SafetyHumansRNA, ViralRNA, Viral

Identifiers

PMID35175185
PMCPMC9480969
OpenAlexW4213192385

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.